News | Atrial Fibrillation | December 14, 2022

Field Medical and CardioNXT Collaborate to Deliver Novel Integration of Focal Pulsed Field Ablation And 3D Mapping & Navigation For Treatment of Cardiac Arrhythmias

Verseon’s scientific journey to highly promising therapeutic candidates for cardiovascular disease appears in European Journal of Medicinal Chemistry 

Verseon’s scientific journey to highly promising therapeutic candidates for cardiovascular disease appears in European Journal of Medicinal Chemistry

December 14, 2022 —  Field Medical, Inc. and CardioNXT, Inc. announce a strategic collaboration to provide the first-of-its-kind, purpose built, focal pulsed field ablation (PFA) therapy integrated seamlessly with 3D mapping & navigation.  

Both teams will harness decades of experience in pioneering novel PFA and navigation product solutions in various medical therapy applications. 

"PFA has generated much excitement in the treatment of atrial fibrillation due to an improved safety profile and procedural workflow. However, most of the first generation PFA technologies today are repurposed from other applications and suffer from significant limitations outside a subset of AFib procedures," said Dr. Steven Mickelsen, CEO, Field Medical. "This collaboration brings together second generation focal PFA and AI-based cardiac mapping—a combination set to revolutionize catheter ablation across the full spectrum of treatable arrhythmias." 

This new collaboration will accelerate development of novel integrated solutions aimed at improving safety and efficacy while minimizing need for x-rays used in cardiac catheter ablation, a market that has grown to $6B per year globally. Accurate navigation is critical to the heart rhythm treatment especially outside the atria where magnetic localization can dramatically improve positioning during the treatment of life threatening ventricular tachycardia. 

"We are excited to collaborate with Field Medical to build a purpose-built system from the ground up that incorporates PFA, Contact Force Sensing, Electromagnetic Localization, and AI-enabled mapping capabilities," said Jerome Edwards, CEO, CardioNXT. "We believe this will create a first of its kind completely integrated total solution to identify sources of cardiac arrhythmias and deliver therapy to those targets more efficaciously than ever before." 

For more information: https://www.fieldmedicalinc.com/ 

For more information: www.verseon.com 


Related Content

News | Atrial Fibrillation

March 27, 2023 — Patients with atrial fibrillation (AF) benefit from early rhythm control therapy. It reduces ...

Home March 27, 2023
Home
News | Atrial Fibrillation

March 9, 2023 — People with a recent diagnosis of atrial fibrillation (AF), the most common irregular heart rhythm, have ...

Home March 09, 2023
Home
News | Atrial Fibrillation

March 8, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home March 08, 2023
Home
News | Atrial Fibrillation

March 6, 2023 — A new ablation technology known as pulsed field ablation was successful at eliminating episodes of ...

Home March 06, 2023
Home
News | Atrial Fibrillation

February 14, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home February 14, 2023
Home
News | Atrial Fibrillation

February 9, 2023 — The Cardiomatics certified online SaaS platform provides world-class Holter ECG analytics to support ...

Home February 09, 2023
Home
News | Atrial Fibrillation

February 6, 2023 — In the largest genetic study of heart arrhythmia to date, researchers led by Kazuo Miyazawa and Kaoru ...

Home February 06, 2023
Home
News | Atrial Fibrillation

February 2, 2023 — Abbott today announced two approvals as part of its growing suite of electrophysiology products in ...

Home February 02, 2023
Home
News | Atrial Fibrillation

February 1, 2023 — Periodontitis, a gum disease, can lead to a litany of dental issues from bad breath to bleeding and ...

Home February 01, 2023
Home
News | Atrial Fibrillation

November 10, 2022 — Biosense Webster, Inc., the global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home November 10, 2022
Home
Subscribe Now